Theranostics

Theranostics, a personalized nuclear medicine strategy, is experiencing an exponential and global expansion.¹

Theranostics Specialty

    Rapid expansion

    Substantial market investment is leading to exponential growth in patients and procedures.

    Rapid pace of innovation

    Theranostics has a pipeline of potential new indications, therapies, and processes.

    Rapid advancement of AI

    With AI, personalized theranostics may be able to become the routine standard of care.

    Rapid growth of new centers

    The single sourcing of total molecular imaging needs is helping get clinical theranostics programs off the ground.
    Precise and personalized

    Therapy + diagnostics = Renewed hope

    The approach of zeroing in on tumor receptors with positron- and gamma-emitting radioligands to visualize cancer cells, and beta- or alpha-emitting radioligands to destroy cancer cells makes theranostics the quintessential targeted care pathway.

    When other strategies have failed, theranostics has given hope that patient's lives might be extended so that they may have more time to spend with their loved ones

    Radioligand therapies have historically been one of the last treatments for cancer, but new evidence shows positive results if this type of care is used earlier, closer to when cancer is diagnosed.² Because of the limited side effects of this precision treatment, it is now a pre-chemo therapy option for some patients.

    Testimonials³

    The next major pillar of cancer care

    "Innovative theranostics therapies have the potential to be the next major pillar of
    cancer care, impacting the lives of hundreds of thousands of people and their families."

    Prof. Ken Hermann

    Head of Nuclear Medicine Department, University Hospital Essen, Germany

    A new world of possibilities

    Many new indications treatable with radioligand therapies could be just around the corner⁴

    Already chosen to treat patients with mCRPC, neuroendocrine tumors, thyroid and other cancers, researchers are exploring⁵ a wider range of cancers, such as brain, breast, pancreatic, and ovarian, that may be treatable with radioligand therapies in the next five to ten years.

    23 potential new radiopharmaceutical therapies could be approved by 2028⁶

    Radionuclides like ¹⁷⁷Lu, ¹³¹I, and ⁹⁰Y have established themselves as effective cancer treatments.⁶ In the next few years, researchers are working to add several more radionuclides to the fight against cancers, including two alpha-emitting candidates, ²¹²Pb and ²²⁵Ac.⁵

    Radioligand therapy may throw open the treatment landscape

    Hundreds of clinical trials⁵ are well underway to explore the efficacy of radioligand therapy in battling many cancers. About a tenth of those trials are already in the late stages.

    A patient's theranostics journey

    The theranostics care pathway PSMA example with ¹⁷⁷Lu-PSMA

    01 / 04

    Patient qualification

    Does the prostate cancer express PSMA, and if so, are the disease stage and the patient's clinical condition appropriate for treatment with ¹⁷⁷Lu-PSMA therapy? To find out, a radiopharmaceutical injection of ⁶⁸Ga-PSMA, or ¹⁸F-PSMA, can be given to the patient who is then imaged on a PET/CT or PET/MR scanner.

    Establishing your theranostics program as a Clinical Center of Excellence

    Through a theranostics operations asssessment, GE HealthCare can walk you through a step-by-step proposal of options to effectuate development of your program and help grow it into a success.

    Top-of-the-line discovery, diagnosis, and treatment monitoring solutions

    GE HealthCare believes so strongly in the promise of theranostics, we have optimized many of our products and solutions specifically for theranostics.

    Comprehensive solutions

    GE HealthCare enabling theranostics

    GE HealthCare makes it easy to single source end-to-end solutions for your new theranostics program. From tracer production to pathway management to PET and SPECT imaging, GE HealthCare has support for your discovery, diagnosis, and treatment monitoring needs.
    Thought leaders

    Prominent experts in theranostics research and clinical application share their knowledge

    01 / 02

    Establishing a theranostics program: practical considerations

    Dr. Medhat M. Osman, Chairman of Nuclear Medicine at St. Louis University speaks at SNMMI 2022

    Insights

    Dive deeper into theranostics

     

    Part 1: The human side of theranostics

     

    Part 2: Theranostics program design

     

    Part 3: Theranostics strategic partnership

     

    Part 4: Pioneering the future of theranostics

     

    Fortifying the pathway to hope with theranostics

     

    Evolving the promise of precision medicine with theranostics

     

    The new future of molecular medicine—targeted molecular imaging and therapeutics

     

    The new future of MI: leveraging molecular imaging solutions to their full potential

    Have a question? We would love to hear from you.

    References
    1. Bodei, L., Herrmann, K., Schöder, H. et al. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol 19, 534–550 (2022). https://doi.org/10.1038/s41571-022-00652-y
    2. Pomykala KL, Hadaschik BA, Sartor O, et al. 2023. Next generation radiotheranostics promoting precision medicine. Annals of Oncology 34(6): 507-19
    3. Statements made by GE HealthCare customers are based on their own opinions and experiences and on results that were achieved in their unique setting. Since there is no typical hospital and many variables exist, such as hospital size, case mix, etc., there can be no guarantee that other customers will achieve the same results.
    4. MEDraysintell Nuclear Medicine (Part 3) - Early-Stage Radiopharmaceuticals - Edition 2023
    5. Source: Based on numbers listed in clinicaltrials.gov as of March 2025
    6. MEDraysintell Nuclear Medicine (Part 1) - Marketed Radiopharmaceuticals - Edition 2023
    7. Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked.

    JB33439XX